187 related articles for article (PubMed ID: 33932086)
21. ZD6474 enhances paclitaxel antiproliferative and apoptotic effects in breast carcinoma cells.
Sarkar S; Mazumdar A; Dash R; Sarkar D; Fisher PB; Mandal M
J Cell Physiol; 2011 Feb; 226(2):375-84. PubMed ID: 20665703
[TBL] [Abstract][Full Text] [Related]
22. Paclitaxel resistance is associated with switch from apoptotic to autophagic cell death in MCF-7 breast cancer cells.
Ajabnoor GM; Crook T; Coley HM
Cell Death Dis; 2012 Jan; 3(1):e260. PubMed ID: 22278287
[TBL] [Abstract][Full Text] [Related]
23. Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism.
Goodman CR; Sato T; Peck AR; Girondo MA; Yang N; Liu C; Yanac AF; Kovatich AJ; Hooke JA; Shriver CD; Mitchell EP; Hyslop T; Rui H
Oncogene; 2016 Mar; 35(11):1373-85. PubMed ID: 26096934
[TBL] [Abstract][Full Text] [Related]
24. B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation.
Liu H; Tekle C; Chen YW; Kristian A; Zhao Y; Zhou M; Liu Z; Ding Y; Wang B; Mælandsmo GM; Nesland JM; Fodstad O; Tan M
Mol Cancer Ther; 2011 Jun; 10(6):960-71. PubMed ID: 21518725
[TBL] [Abstract][Full Text] [Related]
25. Cyclin-Dependent Kinase 11 (CDK11) Is Required for Ovarian Cancer Cell Growth In Vitro and In Vivo, and Its Inhibition Causes Apoptosis and Sensitizes Cells to Paclitaxel.
Liu X; Gao Y; Shen J; Yang W; Choy E; Mankin H; Hornicek FJ; Duan Z
Mol Cancer Ther; 2016 Jul; 15(7):1691-701. PubMed ID: 27207777
[TBL] [Abstract][Full Text] [Related]
26. Long noncoding RNA CASC2 promotes paclitaxel resistance in breast cancer through regulation of miR-18a-5p/CDK19.
Zheng P; Dong L; Zhang B; Dai J; Zhang Y; Wang Y; Qin S
Histochem Cell Biol; 2019 Oct; 152(4):281-291. PubMed ID: 31352515
[TBL] [Abstract][Full Text] [Related]
27. Taxol-induced growth arrest and apoptosis is associated with the upregulation of the Cdk inhibitor, p21WAF1/CIP1, in human breast cancer cells.
Choi YH; Yoo YH
Oncol Rep; 2012 Dec; 28(6):2163-9. PubMed ID: 23023313
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA 100 sensitizes luminal A breast cancer cells to paclitaxel treatment in part by targeting mTOR.
Zhang B; Zhao R; He Y; Fu X; Fu L; Zhu Z; Fu L; Dong JT
Oncotarget; 2016 Feb; 7(5):5702-14. PubMed ID: 26744318
[TBL] [Abstract][Full Text] [Related]
29. ZNF217 confers resistance to the pro-apoptotic signals of paclitaxel and aberrant expression of Aurora-A in breast cancer cells.
Thollet A; Vendrell JA; Payen L; Ghayad SE; Ben Larbi S; Grisard E; Collins C; Villedieu M; Cohen PA
Mol Cancer; 2010 Nov; 9():291. PubMed ID: 21059223
[TBL] [Abstract][Full Text] [Related]
30. Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin.
Wang S; Huang X; Lee CK; Liu B
Oncogene; 2010 Jul; 29(29):4225-36. PubMed ID: 20498641
[TBL] [Abstract][Full Text] [Related]
31. [The effect of LAMP2A shRNA on the resistance of breast cancer cells to paclitaxel].
Han Q; Chen S; Yang M; Zhang Z; Chen A; Hu C; Li S
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Apr; 30(4):351-4. PubMed ID: 24721399
[TBL] [Abstract][Full Text] [Related]
32. Differential effect of anti-apoptotic genes Bcl-xL and c-FLIP on sensitivity of MCF-7 breast cancer cells to paclitaxel and docetaxel.
Wang Z; Goulet R; Stanton KJ; Sadaria M; Nakshatri H
Anticancer Res; 2005; 25(3c):2367-79. PubMed ID: 16080463
[TBL] [Abstract][Full Text] [Related]
33. Estrogen receptor α attenuates therapeutic efficacy of paclitaxel on breast xenograft tumors.
Chang J; Sui M; Fan W
Breast Cancer Res Treat; 2012 Aug; 134(3):969-80. PubMed ID: 22374518
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of centrosomal protein Nlp confers breast carcinoma resistance to paclitaxel.
Zhao W; Song Y; Xu B; Zhan Q
Cancer Biol Ther; 2012 Feb; 13(3):156-63. PubMed ID: 22353935
[TBL] [Abstract][Full Text] [Related]
35. Resveratrol augments paclitaxel treatment in MDA-MB-231 and paclitaxel-resistant MDA-MB-231 breast cancer cells.
Sprouse AA; Herbert BS
Anticancer Res; 2014 Oct; 34(10):5363-74. PubMed ID: 25275030
[TBL] [Abstract][Full Text] [Related]
36. Paclitaxel sensitivity of breast cancer cells requires efficient mitotic arrest and disruption of Bcl-xL/Bak interaction.
Flores ML; Castilla C; Ávila R; Ruiz-Borrego M; Sáez C; Japón MA
Breast Cancer Res Treat; 2012 Jun; 133(3):917-28. PubMed ID: 22076480
[TBL] [Abstract][Full Text] [Related]
37. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
38. Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells.
Hu K; Law JH; Fotovati A; Dunn SE
Breast Cancer Res; 2012 Feb; 14(1):R22. PubMed ID: 22309939
[TBL] [Abstract][Full Text] [Related]
39. CyclinG1 Amplification Enhances Aurora Kinase Inhibitor-Induced Polyploid Resistance and Inhibition of Bcl-2 Pathway Reverses the Resistance.
Zhang W; Xu J; Ji D; Li Z; He W; Yang F; Lan H; Wang Y; Wu Z; Liu X; Huang S; Li L; Zhou W
Cell Physiol Biochem; 2017; 43(1):94-107. PubMed ID: 28848145
[TBL] [Abstract][Full Text] [Related]
40. Establishment of paclitaxel-resistant breast cancer cell line and nude mice models, and underlying multidrug resistance mechanisms in vitro and in vivo.
Chen SY; Hu SS; Dong Q; Cai JX; Zhang WP; Sun JY; Wang TT; Xie J; He HR; Xing JF; Lu J; Dong YL
Asian Pac J Cancer Prev; 2013; 14(10):6135-40. PubMed ID: 24289639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
